国药控股(01099)：国药一致(000028.SZ)预计2025年归母净利约10.55亿元到12.15亿元 同比增长64.20%到89.11%

Group 1 - The core viewpoint of the article is that China National Pharmaceutical Group (国药控股) has announced a significant expected increase in net profit for its subsidiary, China National Pharmaceutical Group Co., Ltd. (国药一致), for the fiscal year 2025 [1] - The company anticipates a net profit attributable to shareholders of the listed company to be between 1.055 billion to 1.215 billion yuan, representing a year-on-year growth of 64.20% to 89.11% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 996 million to 1.156 billion yuan, indicating an increase of 71.38% to 98.91% year-on-year [1]